Abstract
N-Acetyltransferase 2 (NAT2) is involved in Phase II biotransformation of a variety of toxicants. Polymorphisms in the NAT2gene result in a slow acetylator phenotype, which has been associated with various cancers and neurodegenerative diseases. To date most studies investigating NAT2 genotype/phenotype have adopted an RFLP approach, which is both expensive and time-consuming. Using the Wave DNA fragment analysis system, we have developed a fast and robust method of identifying two polymorphisms (C282T and T341C) of the NAT2 gene which allows identification of the most common slow acetylator alleles found in Caucasian populations: NAT2*5, NAT2*6, NAT2*7, and NAT2*14. This was done by comparing phenotype status in 126 samples genotyped by RFLP analysis and also by Wave analysis for the polymorphisms C282T and T341C. All 126 samples analyzed by both RFLP and Wave analysis gave consistent phenotype results and 100% correlation was achieved between the two methods.
Similar content being viewed by others
References
Agundez, J. A. G., Jimenez-Jimenez, F. J., Luengo, A., Molina, J. A., Orti-Pareja, M., Vazquez, A., Ramos, F., Durst, J., Casia, J., Ladero, J., Averaz-Cermenoj, J., & Benitez, J. (1998). Slow Allotypic variants of the NAT2 gene and susceptibility to early-onset Parkinson's Disease. Neurology 51:1587–1592.
Bandmann, O., Vaughan, J., Holmans, P., Marsden, C. D., & Wood, N. W. (1997). Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease. Lancet 350:1136–1139.
Brockmoller, J., Cascorbi, I., Kerb, R., Roots, I. (1996). Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione 5-transferase Ml and TI, microsomal epoxide hydrolase and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res. 56:3915–3925.
Cascorbi, I., Drakoulis, N., Brockmoller, J., Maurer, A., Sperling, K., Roots I. (1995). Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: Correlation with phenotypic activity. Am. J. Hum. Genet. 57:581–592.
Cascorbi, I., & Roots, I. (1998). Pitfalls in N-acetyltransferase genotyping. Pharmacogenetics 9:123–127.
Doll, M. A., Fretland, Ad. J., Deitz, A. C., & David, W. H. (1995). Determination of human NAT2 acetylator genotype by restriction fragment-lengh polymorphism and allele specific amplification. Anal. Biochem. 231:413–420.
Grant, D. M. (1993). Molecular genetics of the N-acetytransferases. Pharmacogenetics 3:45–50.
Henning, S., Cascorbi, I., Munchow, B., Jahnke, V., Roots, I. (1999). Association of arylamine N-acetyltransferase NAT1 and NAT2 genotypes to larngeal cancer risk. Pharmacogenetics 9:103–111.
Hirvonen, A., Saarkioski, S. T., Linnainmaa, K., Koskinen Kari, Husgafvel-Pursainen Kirsti, Mattson Karin, and Vainioh, H. (1996). Glutathione 5-transferase and N-acetyltransferase genotypes in asbestos-associated pulmonary disorders. J. Nat. Cancer Inst. 88:1853–1856.
Mironova, N. J., Wilkman, H., Brouchardy, C., Mitrunen, K., Dayer, P., Benhamou, S., & Hirvonen, A. (1999). Role of arylamine N-acetltransferase 1 and 2 (NAT1 and NAT2) genotypes in susceptibility to oral/pharyngeal and laryngeal cancers. Pharmacogenetics 9:533–537.
Risch, A., Wallace, D. M. A., Bathersa, S., Sim, E. (1995). Slow N-acetylation genotype is a susceptibilty factor in occupational and smoking related bladder cancer. Hum. Mol. Genet. 4:231–236.
Rocha, L., Garcia, C., de Medoca, A., Gil, J. P., Bishop, D. T., Lechner, M. C. (1999). N-Acetyltransferase (NAT2) genotype and susceptibility to sporadic Alzeimer's disease. Pharmacogenetics 9:9–15.
Smith, C. A. D., Wadelius, M., Gough A. C., Harrison, D. J., Roland, W. C., Rane, A. (1997). A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. J. Med. Genet. 34:758–760.
Taningher, M., Malcarne, D., Izzotti, A., Ugolini, D., Parodi, S. (1999). Drug metabolism polymorphisms as modulators of cancer susceptibility. Mutat. Res. 436:227–261.
Underhill, P. A., Jin, L., Zemans, R., Oefner, P. J., Cavalli-Sforza, L. L. (1996). A pre-Columbian Y chromosome-specific transition and its implications for human evolutionary history. Proc. Natl. Acad. Sci. U.S.A. 93:196–200.
Vatsis, K. P., Weber, W. W., Bell D. A., Dupret, J. M., Price-Evans, D. A., Grant, D. M., et al. (1995). Nomenclature for N-acetyltransferases. Pharmacogenetics 1:1–17.
Rights and permissions
About this article
Cite this article
Osborne, A., Bell, C., Grant, F. et al. A Rapid Method of Screening for N-Acetyltransferase (NAT2) Phenotype by Use of the WAVE DNA Fragment Analysis System. Biochem Genet 41, 405–411 (2003). https://doi.org/10.1023/B:BIGI.0000007775.61514.e8
Issue Date:
DOI: https://doi.org/10.1023/B:BIGI.0000007775.61514.e8